image credit: Unsplash

Moderna Revenue Triples on Soaring Vaccine Sales

Moderna Inc. MRNA -1.16% said that its first-quarter revenue and profit tripled from a year earlier on higher sales of its Covid-19 vaccine and that a fall booster-shot campaign could drive continued sales gains.

The biotechnology company’s revenue topped $6 billion in the period ended March 31, beating analyst expectations and rising from $1.94 billion a year earlier, driven almost entirely by sales of its messenger RNA-based vaccine, branded as Spikevax.

Read More on The Wall Street Journal